Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
11.09.24 | Merck KGaA introduces single-use reactor to accelerate ADC manufacturing | ||
10.09.24 | Osivax and KM Biologics sign deal for influenza vaccine in Japan | ||
09.09.24 | Superluminal Medicines secures $120m in Series A funding round | ||
06.09.24 | Moderna's updated Covid-19 vaccine receives positive EMA CHMP opinion | ||
05.09.24 | Novartis begins construction works at two RLT manufacturing facilities in US | ||
04.09.24 | UK MHRA grants authorisation for Moderna's updated Covid-19 vaccine | ||
03.09.24 | Skyline Therapeutics secures FDA orphan drug status for RP therapy | ||
02.09.24 | Novavax's updated Covid-19 vaccine receives FDA emergency use authorisation | ||
30.08.24 | Johnson & Johnson seeks FDA approval for generalised myasthenia gravis therapy | ||
29.08.24 | Bayer partners with NextRNA to develop lncRNA-targeting cancer therapies | ||
28.08.24 | Zuellig Pharma and Regeneron sign deal to supply Libtayo in South Korea and Taiwan | ||
27.08.24 | FDA grants orphan drug status for RedHill's opaganib for neuroblastoma | ||
26.08.24 | Moderna's RSV vaccine mRESVIA gains EC approval | ||
23.08.24 | FDA grants orphan drug status to Ractigen's RAG-18 for DMD and BMD | ||
22.08.24 | RedHill launches Talicia in UAE to treat H. pylori infection | ||
21.08.24 | GSK's B7-H3-targeted ADC receives FDA breakthrough therapy status | ||
20.08.24 | FDA grants Fast Track Designation to Arthrosi Therapeutics's AR882 for gout treatment | ||
19.08.24 | EMA validates Type II Variation application for ENHERTU for breast cancer treatment | ||
16.08.24 | Aarvik announces ADC option exercise by collaboration partner ArriVent | ||
14.08.24 | FDA grants priority review for Bavarian Nordic's chikungunya vaccine BLA | ||
13.08.24 | Persist AI and Nivagen to develop AI-driven LAI manufacturing process | ||
12.08.24 | Sandoz's Enzeevu secures FDA approval for nAMD treatment | ||
09.08.24 | Bavarian Nordic secures $156.8m US vaccine deal |